OPDIVO QVANTIG
OPDIVO QVANTIG is a combination of nivolumab, a PD-1 blocking antibody, and hyaluronidase, an endoglycosidase. It is indicated for the treatment of adult and pediatric patients with various stages of melanoma, renal cell carcinoma, and non-small cell lung cancer. The drug is utilized across several clinical settings, including first-line therapy, adjuvant treatment following surgery, and for patients with metastatic disease who have progressed on prior chemotherapy.
How OPDIVO QVANTIG Works
Nivolumab is a monoclonal antibody that binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands. By disrupting this pathway, the drug prevents the inhibition of T-cell activity and releases the body's anti-tumor immune response. The hyaluronidase component functions by temporarily depolymerizing hyaluronan, a polysaccharide in the subcutaneous tissue's extracellular matrix. This increases the permeability of the tissue at the injection site to facilitate drug delivery, a process that is reversible within 48 hours.
Details
- Status
- Prescription
- First Approved
- 2024-12-27
- Routes
- SUBCUTANEOUS, INJECTION
- Dosage Forms
- INJECTABLE
OPDIVO QVANTIG Approval History
What OPDIVO QVANTIG Treats
3 indicationsOPDIVO QVANTIG is approved for 3 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Renal Cell Carcinoma
- Melanoma
- Non-Small Cell Lung Cancer
OPDIVO QVANTIG Target & Pathway
ProTarget
An immune checkpoint receptor on T-cells that acts as an 'off switch' for immune responses. Cancer cells often exploit PD-1 by expressing its ligands (PD-L1/PD-L2), allowing tumors to evade immune detection. Blocking PD-1 releases this brake, enabling T-cells to recognize and attack cancer cells.
Pathway Context
PD-1 on T-cells binds to PD-L1/PD-L2 on tumor cells, suppressing immune attack
A protein expressed on tumor cells and immune cells that binds to PD-1 on T-cells, suppressing immune responses. Many cancers overexpress PD-L1 to avoid immune attack. Blocking PD-L1 prevents this immune suppression, allowing the body's T-cells to fight cancer.
A second ligand for PD-1, expressed on antigen-presenting cells and some tumors. PD-L2 binds PD-1 with higher affinity than PD-L1 but is less widely expressed. Drugs blocking PD-1 prevent both PD-L1 and PD-L2 interactions.
OPDIVO QVANTIG Competitors
Pro10 other drugs also target PD-1. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (PD-1). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to OPDIVO QVANTIG
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
OPDIVO QVANTIG FDA Label Details
ProIndications & Usage
FDA Label (PDF)OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. • adult patie...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.